VRTX
Vertex Pharmaceuticals Incorpor · Healthcare · Biotechnology
TECHSellZACKSHold
R500#357 today
$504.73
-0.40% today · -4.08% 1W
Oct 2 close or latest
PreviewWhy it's moving
Underperforming without a clear catalyst yet
- VRTX −0.40% on the last session vs SPY +0.74%: −1.1 pts of stock-specific move.
- Aftermath, big drop (Oct 1): After its 61 big drops in the past 5 years, VRTX typically gained 0.5% over the next day (median) and was higher 62% of the time; half the outcomes fell between -0.9% and +1.5%. An ordinary day: +0.1%. Among S&P 500 stocks after big drops, that ranks #13 of 500.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Next report
Nov 2
In 29 days
EPS estimate
−$1.22
−$29.56 to $5.06 · 12 analysts
Revenue estimate
$3.4B
$3.3B to $3.5B
Track record
4/8 beats
last 8 reports · moved ±6.1% on average
Reports
| Reported | Quarter | EPS est. | EPS | EPS surprise | Revenue | Reaction | Gap | 5 days |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 AMC | 2Q2026 | $4.75 | $4.73 | −$0.02 (−0.3%) miss | $3.3B | +1.7% -0.1 vs SPY | +0.1% | +11.3% |
| May 4, 2026 AMC | 1Q2026 | $4.31 | $4.47 | +$0.16 (+3.8%) beat | $3.0B | -1.3% -2.1 vs SPY | +0.5% | +1.2% |
| Feb 12, 2026 AMC | 4Q2025 | $5.15 | $5.03 | −$0.12 (−2.3%) miss | $3.2B | +5.7% +5.6 vs SPY | +1.4% | +2.5% |
| Nov 3, 2025 AMC | 3Q2025 | $4.58 | $4.80 | +$0.22 (+4.9%) beat | $3.1B | -1.0% +0.2 vs SPY | -1.8% | -1.1% |
| Aug 4, 2025 AMC | $4.25 | $4.52 | +$0.27 (+6.4%) beat | — | -20.6% -20.1 vs SPY | -13.6% | -20.7% | |
| May 5, 2025 AMC | $4.29 | $4.06 | −$0.23 (−5.4%) miss | — | -10.0% -9.2 vs SPY | -6.9% | -12.2% | |
| Feb 10, 2025 AMC | $4.02 | $3.98 | −$0.04 (−1.0%) miss | — | -3.1% -3.2 vs SPY | -2.2% | -1.7% | |
| Nov 4, 2024 AMC | $4.13 | $4.38 | +$0.25 (+6.1%) beat | — | +5.7% +4.5 vs SPY | +2.2% | +6.1% | |
| Aug 1, 2024 AMC | −$11.75 | −$12.83 | −$1.08 (−9.2%) miss | — | -2.2% -0.4 vs SPY | -2.8% | -7.9% | |
| May 6, 2024 AMC | $4.06 | $4.76 | +$0.70 (+17.2%) beat | — | +1.9% +1.8 vs SPY | +1.0% | +6.8% | |
| Feb 5, 2024 AMC | $4.09 | $4.20 | +$0.11 (+2.7%) beat | — | -3.0% -3.3 vs SPY | 0.0% | -2.4% | |
| Nov 6, 2023 AMC | $3.97 | $4.08 | +$0.11 (+2.8%) beat | — | -1.9% -2.2 vs SPY | -2.2% | -1.8% | |
| Aug 1, 2023 AMC | $3.88 | $3.89 | +$0.01 (+0.3%) beat | — | +3.1% +4.5 vs SPY | +0.7% | -0.9% | |
| May 1, 2023 AMC | $3.00 | $3.05 | +$0.05 (+1.7%) beat | — | +0.3% +1.4 vs SPY | 0.0% | -0.3% | |
| Feb 7, 2023 AMC | $3.51 | $3.76 | +$0.25 (+7.1%) beat | — | -4.9% -3.8 vs SPY | -1.8% | -2.7% | |
| Oct 27, 2022 AMC | $3.64 | $4.01 | +$0.37 (+10.2%) beat | — | +9.0% +6.7 vs SPY | +4.9% | +8.1% | |
| Aug 4, 2022 AMC | $3.50 | $3.60 | +$0.10 (+2.9%) beat | — | +4.8% +5.0 vs SPY | -0.6% | +6.3% | |
| May 5, 2022 AMC | $3.54 | $3.52 | −$0.02 (−0.6%) miss | — | -4.7% -4.1 vs SPY | -3.8% | -9.6% | |
| Jan 26, 2022 AMC | $3.29 | $3.37 | +$0.08 (+2.4%) beat | — | +0.7% +1.2 vs SPY | +1.1% | +11.9% | |
| Nov 2, 2021 AMC | $3.07 | $3.56 | +$0.49 (+16.0%) beat | — | +4.2% +3.6 vs SPY | +3.4% | +5.3% | |
| Jul 29, 2021 AMC | $2.38 | $3.11 | +$0.73 (+30.7%) beat | — | — | — | — | |
| Apr 29, 2021 AMC | $2.69 | $2.98 | +$0.29 (+10.8%) beat | — | — | — | — | |
| Feb 1, 2021 AMC | $2.55 | $2.51 | −$0.04 (−1.6%) miss | — | — | — | — | |
| Oct 29, 2020 AMC | $2.33 | $2.64 | +$0.31 (+13.3%) beat | — | — | — | — |
BMO = before the open, AMC = after the close. Reaction: the first session that could trade on the report (the same day for BMO, the next session for AMC) against the close before it; "vs SPY" subtracts the S&P 500 over the same session. EPS surprise is in dollars, with the percentage only when the estimate is at least $0.10 (near zero, a small beat would show as hundreds of percent). Revenue surprise needs the estimate from before the report, so it starts with the reports Wallsti saw coming.
Analyst estimates
| Period | EPS | Range | vs year ago | 90-day trend | Revisions 30d | Revenue | vs year ago |
|---|---|---|---|---|---|---|---|
| Current quarter · Sep 30, 2026 | −$1.22 (12) | −$29.56 – $5.06 | -125% | -124.6% | ▲0 ▼2 | $3.4B | +11% |
| Next quarter · Dec 31, 2026 | $4.56 (13) | $4.04 – $5.05 | -9% | -9.3% | ▲3 ▼8 | $3.5B | +11% |
| Current year · Dec 31, 2026 | $16.17 (15) | −$2.72 – $19.31 | -12% | -15.5% | ▲0 ▼2 | $13.2B | +10% |
| Next year · Dec 31, 2027 | $20.11 (15) | $17.70 – $22.89 | +24% | -6.4% | ▲1 ▼1 | $14.6B | +10% |
Consensus as of Oct 4, 2026. Source: Yahoo Finance analyst estimates; schedule and timing also from Nasdaq's earnings calendar.